In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.
about
A review of linezolid: the first oxazolidinone antibiotic.In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureusAntibiotic sensitivity profile of bacterial pathogens in postoperative wound infections at a tertiary care hospital in Gujarat, India.Enterococcus faecalis resistant to linezolid: case series and review of the literature.Effect of linezolid on the 50% lethal dose and 50% protective dose in treatment of infections by Gram-negative pathogens in naive and immunosuppressed mice and on the efficacy of ciprofloxacin in an acute murine model of septicemia.Treatment of meningitis due to methicillin-resistant Staphylococcus epidermidis with linezolid.Linezolid: a new antibiotic for newborns and children?Antibiotics and antifungals in neonatal intensive care units: a review.Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection.Synergistic Antimicrobial Effects of Silver/Transition-metal Combinatorial Treatments.Synergistic activity of phenazines isolated from Pseudomonas aeruginosa in combination with azoles against Candida species.In vitro antibacterial screening of six proline-based cyclic dipeptides in combination with β-lactam antibiotics against medically important bacteria.Activity and synergistic antimicrobial activity between diketopiperazines against bacteria in vitro.In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteriaAsarones from Acorus calamus in combination with azoles and amphotericin B: a novel synergistic combination to compete against human pathogenic Candida species in vitro.Pharmacodynamic and response surface analysis of linezolid or vancomycin combined with meropenem against Staphylococcus aureus.In vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureus.In vitro activity of linezolid alone and combined with other antibiotics against clinical enterococcal isolates.Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea.Microplate Alamar blue assay for Staphylococcus epidermidis biofilm susceptibility testing.Managing Severe Community-Acquired Pneumonia Due to Community Methicillin-Resistant Staphylococcus aureus (MRSA).Predicting effects of antibiotic combinations using MICs determined at pharmacokinetically derived concentration ratios: in vitro model studies with linezolid- and rifampicin-exposed Staphylococcus aureus.Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis.Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations.
P2860
Q33363226-28F7141D-063B-475E-BDCF-D15EC00B1F3BQ33556476-E60E8FA7-817E-4B47-BFA6-B3EBC841C859Q35167721-D08861EC-1288-4EFF-AF26-401B2B821848Q35906331-D374E461-80EC-4F4E-AB63-E98E33C54ACDQ36172366-FE84B7AA-6312-48CB-9457-6D0DBA024EFEQ36240752-C2FBB204-EB73-450A-9B33-44388E4A31A3Q36724345-99A62267-41B1-4EA6-9FC3-D46E0767F588Q36740036-88C6243D-C7F1-4475-A6D7-CE04B54E374BQ37115701-11E7524F-9AE0-4CC8-B136-99B6C17ECAC8Q38728622-587A54A4-B46E-4FCD-BD7C-4CC150E23C3DQ38986105-0D30AD8D-DB66-4AC7-A17D-B8EA86C3333BQ39016187-4BD328B5-154A-4655-9EC1-421FEAC51BCFQ39258555-5D7425AD-76A9-4EA0-A660-0BA9DF278319Q40410703-3F52A943-19B6-4EDB-9990-324FF8BBDE38Q41480785-5F6A790C-AED7-4B91-8D0E-28E363D4609DQ41512841-54B40C64-6F8F-47FC-A942-013E5B5162B6Q41832542-AB60646E-1EB4-4E2F-82CE-517E77895687Q41996646-E4A24880-0AA1-4B92-A975-4B0D184CA956Q42111215-52093A6C-E007-49F6-BF7A-5702D4408FA6Q42588626-47F5B0E8-962B-4EE0-B5C8-346358C44E1FQ43636170-E36D77B6-BF7B-4F33-BEA6-2107229687DCQ48247354-328AC47C-66DF-4D75-8B61-16D7C46D0084Q50913254-EA22FDF6-927B-45F4-A081-AF1EEEB44613Q52659763-28867D61-2FA5-41CD-830D-D2B2F0979054
P2860
In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
In vitro activities of linezol ...... ected gram-negative organisms.
@ast
In vitro activities of linezol ...... ected gram-negative organisms.
@en
type
label
In vitro activities of linezol ...... ected gram-negative organisms.
@ast
In vitro activities of linezol ...... ected gram-negative organisms.
@en
prefLabel
In vitro activities of linezol ...... ected gram-negative organisms.
@ast
In vitro activities of linezol ...... ected gram-negative organisms.
@en
P2860
P1476
In vitro activities of linezol ...... ected gram-negative organisms.
@en
P2093
Gary E Zurenko
Michael T Sweeney
P2860
P304
P356
10.1128/AAC.47.6.1902-1906.2003
P407
P577
2003-06-01T00:00:00Z